Spots Global Cancer Trial Database for enzyme inhibitor therapy

Every month we try and update this database with for enzyme inhibitor therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery	NCT00258297	Esophageal Canc...	gefitinib conventional su... enzyme inhibito... neoadjuvant the... protein tyrosin... surgery	18 Years -	University of Rochester
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma	NCT00265928	Lymphoma	bortezomib rituximab antibody therap... biological ther... enzyme inhibito... monoclonal anti...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT00124644	Leukemia	cytarabine daunorubicin hy... etoposide tipifarnib chemotherapy enzyme inhibito... high-dose chemo...	18 Years - 59 Years	National Cancer Institute (NCI)
Talabostat in Treating Patients With Metastatic Kidney Cancer	NCT00489710	Kidney Cancer	talabostat mesy... enzyme inhibito... flow cytometry laboratory biom... non-specific im...	19 Years - 120 Years	University of Nebraska
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix	NCT00072540	Stage 0 Cervica... High-grade Squa...	celecoxib anti-cytokine t... antiangiogenesi... biological ther... cancer preventi... chemoprevention... enzyme inhibito... growth factor a...	18 Years -	SWOG Cancer Research Network
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors	NCT00227773	Gastrointestina... Islet Cell Carc...	octreotide acet... vatalanib anti-cytokine t... antiangiogenesi... biological ther... endocrine thera... enzyme inhibito... growth factor a... hormone therapy protein tyrosin... somatostatin an...	18 Years - 120 Years	Eastern Cooperative Oncology Group
BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer	NCT00040989	Stage IV Renal ... Recurrent Renal...	BAY 56-3722 enzyme inhibito...	18 Years -	National Cancer Institute (NCI)
Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients	NCT00483457	Solid Tumor	enzyme inhibito... protein express... immunohistochem... laboratory biom... biopsy	18 Years -	Vanderbilt-Ingram Cancer Center
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix	NCT00072540	Stage 0 Cervica... High-grade Squa...	celecoxib anti-cytokine t... antiangiogenesi... biological ther... cancer preventi... chemoprevention... enzyme inhibito... growth factor a...	18 Years -	SWOG Cancer Research Network
S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix	NCT00072540	Stage 0 Cervica... High-grade Squa...	celecoxib anti-cytokine t... antiangiogenesi... biological ther... cancer preventi... chemoprevention... enzyme inhibito... growth factor a...	18 Years -	SWOG Cancer Research Network
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma	NCT03229278	Lymphoma Metastatic Mali... Metastatic Mela... Metastatic Rena... Recurrent Bladd... Recurrent Class... Recurrent Head ... Recurrent Lymph... Recurrent Malig... Recurrent Renal... Stage III Bladd... Stage III Lymph... Stage III Non-S... Stage III Renal... Stage III Skin ... Stage IIIA Non-... Stage IIIA Skin... Stage IIIB Non-... Stage IIIB Skin... Stage IIIC Skin... Stage IV Bladde... Stage IV Lympho... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Bladd... Stage IVB Bladd... Unresectable He... Unresectable So...	Enzyme Inhibito... Laboratory Biom... Nivolumab Pembrolizumab	18 Years -	Rutgers, The State University of New Jersey
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors	NCT00227773	Gastrointestina... Islet Cell Carc...	octreotide acet... vatalanib anti-cytokine t... antiangiogenesi... biological ther... endocrine thera... enzyme inhibito... growth factor a... hormone therapy protein tyrosin... somatostatin an...	18 Years - 120 Years	Eastern Cooperative Oncology Group
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT00124644	Leukemia	cytarabine daunorubicin hy... etoposide tipifarnib chemotherapy enzyme inhibito... high-dose chemo...	18 Years - 59 Years	National Cancer Institute (NCI)
BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer	NCT00040989	Stage IV Renal ... Recurrent Renal...	BAY 56-3722 enzyme inhibito...	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: